Aoti

Aoti EBIT Growth

The Year-over-Year EBIT Growth of Aoti (AOTI.L) as of Oct 30, 2026 is 355.46 %. In the previous year, Year-over-Year EBIT Growth was 122.67 % — a change of 189.78% (higher).

EBIT Growth

355.46 %

YoY

189.78%

Last updated:

Year-over-Year EBIT Growth of Aoti is 2025 355.46 % . Year-over-Year EBIT Growth of Aoti was 2024 122.67 % . It decreases by 189.78% higher compared to the previous year.

The Aoti EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2022
-105.64 USD
Jan 1, 2023
-2,981.65 USD
Jan 1, 2024
122.67 USD
Jan 1, 2025
355.46 USD
The Aoti EBIT Growth history
YEAREBIT GrowthYoY
355.46 %+189.78%
122.67 %-104.11%
-2,981.65 %+2,722.51%
-105.64 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aoti Stock analysis

What does Aoti do? Aoti Inc generates revenue through its wound care technology products, primarily TWO2 therapy and NEXA Negative Pressure Wound Therapy (NPWT). The company's TWO2 therapy solutions include TWO2 Extremity Chamber and TWO2 Multi-Patch, designed for patient-administered treatment of chronic wounds. NEXA NPWT System is a disposable, multi-week solution for wound care, targeting healthcare providers who manage chronic wound cases. Aoti focuses on enhancing access to care and improving clinical outcomes for patients with chronic conditions, leveraging robust clinical evidence to support its products' safety and efficacy. Healthcare providers and institutions purchasing TWO2 and NEXA systems form the primary customer segment, driven by the need for clinically proven wound care solutions. The company's products are positioned to address chronic wound management globally, with emphasis on patient quality of life and health equity. Aoti's business model centers on delivering evidence-based therapies that improve patient outcomes while meeting healthcare systems' demands for effective, efficient care delivery. The company's revenue streams are derived from direct sales of TWO2 and NEXA systems to healthcare facilities and practitioners. Product offerings are structured to support both acute and chronic wound care needs, with TWO2 being a multi-modality patient-administered therapy and NEXA providing a flexible, disposable NPWT system. Aoti's focus on clinical evidence ensures its solutions align with healthcare providers' requirements for safety and efficacy in wound treatment. Aoti is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aoti stock

Year-over-Year EBIT Growth of Aoti is 355.46 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Aoti since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Aoti historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Aoti

All Key Metrics — Aoti